Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) Invested Capital (2018 - 2025)

Historic Invested Capital for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $265.5 million.

  • Neurogene's Invested Capital rose 9311.02% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.5 million, marking a year-over-year increase of 9311.02%. This contributed to the annual value of $310.5 million for FY2024, which is 6679.38% up from last year.
  • Neurogene's Invested Capital amounted to $265.5 million in Q3 2025, which was up 9311.02% from $273.3 million recorded in Q2 2025.
  • Neurogene's 5-year Invested Capital high stood at $310.5 million for Q4 2024, and its period low was $75.2 million during Q3 2023.
  • Moreover, its 3-year median value for Invested Capital was $170.9 million (2024), whereas its average is $184.3 million.
  • Over the last 5 years, Neurogene's Invested Capital had its largest YoY gain of 11002.86% in 2024, and its largest YoY loss of 6679.38% in 2024.
  • Neurogene's Invested Capital (Quarter) stood at $186.1 million in 2023, then surged by 66.79% to $310.5 million in 2024, then fell by 14.47% to $265.5 million in 2025.
  • Its Invested Capital was $265.5 million in Q3 2025, compared to $273.3 million in Q2 2025 and $291.8 million in Q1 2025.